From Prototype to Profit: Commercialization Insights

AI data firm Hyperscale Data ties its fate to Bitcoin, with a treasury nearing its market value. A bold strategy or a risky gambit amid a major pivot?

Formerly Fairmatic, LEEO launches with a new CEO and VC backing to tackle the broken commercial auto market with AI. Can its data-driven model succeed?

Cerro de Pasco Resources locks in a vital community deal in Peru, a key step in a $400M plan to turn a century of mining waste into a profitable venture.

Fast Track Group partners with CloudX to merge celebrity power with influencer trust. Can this hybrid model unlock profit in the complex APAC market?

In the heart of oil country, a new boom is taking shape. New Era Energy & Digital is building a gigawatt-scale AI campus, but can it win the infrastructure race?

Amid LNG market fluctuations, Dynagas LNG Partners' new repurchase program signals deep financial health and a strategic play to boost unitholder value.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

With new clinical data and recent FDA approval, IceCure Medical's tumor-freezing tech is paving a new, less-invasive path for breast cancer treatment.

A new partnership aims to commercialize Arbli™, the first liquid losartan, leveraging a digital platform to solve patient adherence and capture market share.

The junior explorer is terminating its NWA project option to double down on promising uranium anomalies in Wyoming and a major conductive corridor in Athabasca.

A new $500M USACE contract shows how Tetra Tech is turning advanced AI and data analytics into profitable solutions for America's toxic waste problems.

Secure identity firm CLEAR lands a major CMS contract to overhaul Medicare.gov's login system, signaling a strategic push into the government sector.

NJBIZ honors Tevogen for its innovation, but can the biotech firm turn its ambitious multi-billion-dollar forecasts into reality? A deep dive.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

Sensorion clears a key safety hurdle for its infant hearing loss gene therapy, but early data reveals a tight race to market against formidable rivals.

Galderma secured stringent EU approval to use its Sculptra biostimulator on the body, targeting a billion-dollar market and setting a new industry benchmark.

With new clinical data and major funding, PreciseDx's AI test aims to make breast cancer prognosis faster, cheaper, and more accurate than ever before.

Digital wellness firm Hapbee appoints a tech hedge fund founder to its board. Can this high-stakes move turn bio-signal tech into sustainable profit?

Junior miner Q-Gold poaches a BMO Vice-Chair and a seasoned CEO. Can this new leadership dream team fund and build its promising Quartz Mountain project?

New Athabasca Basin drill results confirm significant uranium finds, positioning IsoEnergy to capitalize on a surging global market and supply crunch.